Acid lipase disease

Familial Lipoprotein Lipase Deficiency: A Rare Inherited Condition, in Which the Normal Breakdown of Fats in the Body is Affected - Global Pipeline Insight Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 2, 2021

The "Familial Lipoprotein Lipase Deficiency - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Familial Lipoprotein Lipase Deficiency - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Familial Lipoprotein Lipase Deficiency - Pipeline Insight, 2020," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Familial Lipoprotein Lipase Deficiency pipeline landscape.
  • Familial Lipoprotein Lipase Deficiency (LPLD) is a rare inherited condition, in which the normal breakdown of fats in the body is affected.
  • Treatment for Familial Lipoprotein Lipase Deficiency aims to control the symptoms and blood triglyceride levels with a very low-fat diet.

Chennai Boy Undergoes First of Its Kind Living Donor Liver Transplant in India for Rare Metabolic Disease

Retrieved on: 
Saturday, September 5, 2020

A 16 years old boy from Chennai who was suffering from decompensated chronic liver disease due to Cholesteryl ester storage disease, has undergone successful liver transplant at Gleneagles Global Health City.

Key Points: 
  • A 16 years old boy from Chennai who was suffering from decompensated chronic liver disease due to Cholesteryl ester storage disease, has undergone successful liver transplant at Gleneagles Global Health City.
  • This is one among the rare genetic liver diseases which affects the liver at childhood and further leads to liver failure as the child grows older.
  • The boy was on his feet from 3rd day post liver transplant and resumed his normal diet from the 5th day onwards.
  • It was the rarest case in India to undergo successful liver transplant for this type of metabolic disorder.

LAL-D Treatment Market Size Worth $954 Million by 2025 : Grand View Research, Inc.

Retrieved on: 
Wednesday, May 1, 2019

SAN FRANCISCO, May 1, 2019 /PRNewswire/ -- The global lysosomal acid lipase deficiency (LAL-D) treatment market size is likely to reach USD 954 million by 2025, as per a new report by Grand View Research, Inc., exhibiting a 10.8% CAGR during the forecast period.

Key Points: 
  • SAN FRANCISCO, May 1, 2019 /PRNewswire/ -- The global lysosomal acid lipase deficiency (LAL-D) treatment market size is likely to reach USD 954 million by 2025, as per a new report by Grand View Research, Inc., exhibiting a 10.8% CAGR during the forecast period.
  • High unmet needs, rising prevalence, and increasing uptake of enzyme replacement therapy are some of the primary factors driving the market.
  • Until 2015, the global LAL deficiency treatment market witnessed modest growth due to lack of approved treatments for the disease.
  • Grand View Research has segmented the global lysosomal acid lipase deficiency treatment market based on indication, treatment, and country:
    Lysosomal Acid Lipase Deficiency Indication Outlook (Revenue, USD Million, 2017 - 2025)
    Lysosomal Acid Lipase Deficiency Treatment Outlook (Revenue, USD Million, 2017 - 2025)

LAL-D Treatment Market Size Worth $954 Million by 2025 : Grand View Research, Inc.

Retrieved on: 
Wednesday, May 1, 2019

SAN FRANCISCO, May 1, 2019 /PRNewswire/ -- The global lysosomal acid lipase deficiency (LAL-D) treatment market size is likely to reach USD 954 million by 2025, as per a new report by Grand View Research, Inc., exhibiting a 10.8% CAGR during the forecast period.

Key Points: 
  • SAN FRANCISCO, May 1, 2019 /PRNewswire/ -- The global lysosomal acid lipase deficiency (LAL-D) treatment market size is likely to reach USD 954 million by 2025, as per a new report by Grand View Research, Inc., exhibiting a 10.8% CAGR during the forecast period.
  • High unmet needs, rising prevalence, and increasing uptake of enzyme replacement therapy are some of the primary factors driving the market.
  • Until 2015, the global LAL deficiency treatment market witnessed modest growth due to lack of approved treatments for the disease.
  • Grand View Research has segmented the global lysosomal acid lipase deficiency treatment market based on indication, treatment, and country:
    Lysosomal Acid Lipase Deficiency Indication Outlook (Revenue, USD Million, 2017 - 2025)
    Lysosomal Acid Lipase Deficiency Treatment Outlook (Revenue, USD Million, 2017 - 2025)

Lysosomal Acid Lipase Deficiency Financial Assistance Program Launched by The Assistance Fund

Retrieved on: 
Friday, January 25, 2019

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for individuals living with Lysosomal Acid Lipase Deficiency.

Key Points: 
  • The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for individuals living with Lysosomal Acid Lipase Deficiency.
  • An ultra-rare, chronic, progressive disorder, Lysosomal Acid Lipase Deficiency (LAL-D) is caused by abnormalities in the LIPA gene, which is responsible for the bodys ability to produce the lysosomal acid lipase (LAL) enzyme.
  • The Assistance Fund is an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles and other health-related expenses.
  • The Assistance Fund currently manages more than 50 programs each of which covers the FDA-approved medications that treat a specific disease.

Lysosomal Disease Treatments: Technologies and Global Markets

Retrieved on: 
Monday, September 17, 2018

They are rare, inborn defects and have a combined incidence rate of 1 in 1,500 to 7,000 live births.

Key Points: 
  • They are rare, inborn defects and have a combined incidence rate of 1 in 1,500 to 7,000 live births.
  • In lysosomal storage diseases there is deficiency of 1 or more of themany catabolic enzymes that are located within the lysosome.
  • The last decade has witnessed major advances in our understanding of the clinical, biochemical and genetical aspects of lysosomal storage diseases.
  • U.S. is the major market for lysosomal storage disease treatment.